Want to see FR:ALAFY full AI Analyst Report?
Top Page
AFYREN
(ALAFY)
Select Model
Select Model
Rating:45Neutral
Price Target:
€2.00
▼(-27.01% Downside)
Action:Reiterated
Date:09/17/26
The score is driven primarily by weak financial performance—shrinking revenue, deep losses, and persistent cash burn—partly cushioned by a relatively strong, low-debt balance sheet. Technical indicators also lean bearish with the stock trading below key moving averages and negative MACD. Valuation provides limited support because earnings are negative and there is no dividend yield provided.
Positive Factors
Low Financial Leverage
The substantial reduction in debt and low leverage give AFYREN greater financial flexibility than its loss-making results alone would suggest. This balance-sheet capacity can help the company absorb operating volatility and support its industrial development while it works toward sustainable profitability.
Negative Factors
Declining Revenue
Repeated revenue contraction indicates that AFYREN has not yet translated its technology and product offering into dependable commercial expansion. Continued top-line decline can limit operating leverage, weaken customer and production scale benefits, and make a return to sustainable profitability more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
The substantial reduction in debt and low leverage give AFYREN greater financial flexibility than its loss-making results alone would suggest. This balance-sheet capacity can help the company absorb operating volatility and support its industrial development while it works toward sustainable profitability.
Read all positive factors
AFYREN (ALAFY) vs. iShares MSCI France ETF (EWQ)
Market Cap
€87.81M
Dividend YieldN/A
Average Volume (3M)12.33K
Price to Earnings (P/E)―
Beta (1Y)0.04
Revenue Growth-13.62%
EPS Growth54.46%
CountryFR
Employees149
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)-0.20
Shares Outstanding38,852,520
10 Day Avg. Volume8,806
30 Day Avg. Volume12,327
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.22
Price to Sales (P/S)33.31
P/FCF Ratio-14.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.64
Revenue Forecast (FY)€4.15M
AFYREN Business Overview & Revenue Model
Company Description
AFYREN SAS provides biobased products to replace petroleum-based molecules in France. The company offers acetic, propionic, butyric and isobutyric, valeric and isovaleric, and caproic acids. Its products are used in the flavors and fragrances, lub...
How the Company Makes Money
AFYREN makes money primarily by selling bio-based organic acids produced via its proprietary fermentation technology and associated downstream purification at industrial scale. The company’s core revenue model is product sales: it supplies custome...
AFYREN Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.33M | 2.27M | 2.86M | 3.38M | 3.46M | 3.04M |
| Gross Profit | -10.71M | -5.49M | -174.00K | 645.00K | 1.06M | 1.47M |
| EBITDA | -11.42M | -6.81M | -8.81M | -8.59M | -4.71M | -2.78M |
| Net Income | -5.01M | -14.37M | -9.75M | -9.59M | -9.20M | -3.61M |
Balance Sheet | ||||||
| Total Assets | 139.25M | 67.14M | 58.56M | 70.43M | 84.82M | 93.15M |
| Cash, Cash Equivalents and Short-Term Investments | 17.30M | 35.16M | 33.65M | 49.66M | 62.40M | 67.36M |
| Total Debt | 40.90M | 2.42M | 3.31M | 4.79M | 8.54M | 8.95M |
| Total Liabilities | 67.49M | 4.19M | 5.86M | 8.63M | 13.84M | 15.29M |
| Stockholders Equity | 71.76M | 62.10M | 52.70M | 61.80M | 70.98M | 77.86M |
Cash Flow | ||||||
| Free Cash Flow | -15.31M | -5.29M | -5.84M | -5.60M | -3.83M | -3.06M |
| Operating Cash Flow | -9.84M | -5.09M | -5.62M | -5.04M | -3.30M | -2.71M |
| Investing Cash Flow | -27.49M | -15.25M | -9.11M | -3.08M | -362.00K | -436.00K |
| Financing Cash Flow | 27.17M | 21.96M | -1.28M | -4.66M | -1.14M | 60.77M |
AFYREN Technical Analysis
Negative
2.74
Price Trends
2.51
Negative
2.65
Negative
2.68
Negative
Market Momentum
-0.07
Negative
42.54
Neutral
64.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALAFY, the sentiment is Negative. The current price of 2.74 is above the 20-day moving average (MA) of 2.29, above the 50-day MA of 2.51, and above the 200-day MA of 2.68, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 42.54 is Neutral, neither overbought nor oversold. The STOCH value of 64.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALAFY.
AFYREN Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €1.57B | 16.03 | ― | 1.92% | 0.30% | 0.78% | |
65 Neutral | €115.22B | 30.98 | 13.42% | 1.69% | -1.30% | 3.05% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | €4.30B | 329.71 | 0.92% | 6.42% | -5.73% | -73.67% | |
55 Neutral | €74.86M | 45.33 | 3.51% | 1.47% | 6.97% | -73.50% | |
46 Neutral | €87.05M | -4.33 | -10.62% | ― | ― | ― | |
45 Neutral | €87.81M | -11.44 | -7.49% | ― | -13.62% | 54.46% |
* Basic Materials Sector Average
FR:ALAFY
AFYREN
2.26
0.14
6.60%
FR:AI
Air Liquide
180.90
31.59
21.16%
FR:AKE
Arkema
56.05
8.76
18.51%
FR:ALCRB
Carbios SA
5.15
-1.96
-27.62%
FR:ALBKK
Baikowski SA
20.40
-2.32
-10.23%
FR:CBE
Robertet SA Cert.d'Invest. Em.87
625.00
-82.39
-11.65%
AFYREN Corporate Events
AFYREN’s biosourced propionic acid powers first-of-its-kind skincare launch
Oct 1, 2026
AFYREN is reinforcing its role in sustainable industrial biotechnology by supplying 100% biosourced, COSMOS‑certified propionic acid produced via a low‑carbon, circular fermentation process at its AFYREN NEOXY biorefinery in France. Th...
AFYREN and Terrial Renew Multi‑Year Potassium Fertilizer Alliance
Sep 29, 2026
AFYREN and Terrial have renewed their strategic partnership with a new multi‑year fertilizer supply contract worth several tens of millions of euros, centered on AFYREN’s potassium‑rich fertilizer processed by Terrial and markete...
AFYREN Takes Full Control of Flagship Plant as Production and Pre-Sold Volumes Surge
Sep 24, 2026
AFYREN has strengthened its industrial profile by acquiring the remaining 49% of its AFYREN NEOXY plant, becoming its sole owner and gaining full control over ramp-up and performance investments. The company successfully executed an optimization p...
AFYREN scales bio-based acid output and strengthens climate-resilient positioning
Aug 27, 2026
AFYREN has crossed the milestone of 1,000 tonnes of bio-based acids produced at its AFYREN NEOXY biorefinery since ramp-up began in mid-2025, including more than 200 tonnes since operations resumed in July 2026, signalling its transition to full i...
AFYREN Details Share Capital and Voting Rights Structure as of July 31, 2026
Aug 6, 2026
AFYREN, a French greentech company listed on Euronext Growth Paris, develops biobased, low-carbon carboxylic acids through a circular, biomass-based fermentation process aimed at reducing reliance on fossil resources. Its technology serves a broad...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.